The deadline for abstracts’ submission is September 27, 2020;
Abstracts must be submitted in English;
Only abstracts that contain original data will be accepted;
Abstracts containing data that has been presented or will be presented at a different scientific meeting can be submitted. This information must be provided in the submission form.
Abstracts submitted for publication still pending acceptance by the time of the submission process can be submitted without restrictions.
To submit the papers, it is necessary that the author responsible for submitting the abstract is registered in the event. Payment is not required at the moment of registration. This can be done after the acceptance of your abstract. Other authors who have been registered to the Congress should not resubmit the abstract;
Up to 10 papers will be accepted per enrollee. Those who have already reached this number may only be listed in other abstracts as co-authors;
By submitting the abstract, the authors assume compliance with the laws and ethical norms governing research with human beings and animals, including the approval by the ethics committees in research and clinical ethics in animal research.
The abstract must be submitted exclusively through the Congress website;
Before submitting the abstract, review it carefully. Changes will not be allowed after abstracts’ submission deadline;
All communications relating to the abstract will be sent only via email to the author responsible for the submission;
Results:
Evaluations’ results will be sent via e-mail to the author responsible for the submission;
The person responsible for the abstract’s submission, after obtaining its approval, needs to confirm the payment within 7 days from acceptance letter.
There will be no reimbursement of the paid registration fee in cases of withdrawal or absence in Congress;
The presentation should be made by the author responsible for submitting the abstract. If it is not possible, another author should perform the presentation. The presenter must be enrolled in the event and also have paid the registration fee;
The final decision of the Evaluation Committee is considered supreme, irrevocable and unappealing, and will not be revised. Abstracts that are not accepted for oral presentation can be presented via poster and the authors will be informed of this decision.
Only 01 (one) certificate per abstract presented will be issued. The certificate will be issued following the registered order of authors and sent to the author responsible for the submission;
At least one of the authors must be enrolled, attend the event and present the abstract in order to receive the certificate;
Please note: All materials produced from the submitted abstract (annals, certificates, among others) will be a faithful reproduction of the information submitted by the author. Therefore, it is not possible to make changes in the spelling of the title, abstract or authors after the abstracts’ submission deadline. The information provided is the sole responsibility of the author who submit it.
Themes
Antiphospholipid syndrome
Autoinflammatory and Rare Diseases
Bioethics, Education and Information Management
Clinical Laboratory Techniques
Complementary and alternative Therapies
Crystal-related and metabolic Arthropathies
Epidemiology, Public health, Economics
Fibromyalgia and pain syndromes
Imaging in Rheumatology
Infection-related Rheumatic diseases
Muscular Diseases
Orthopedics, Soft-tissue rheumatisms, Low back pain
Osteoarthritis
Osteoporosis and Metabolic Bone Diseases
Pediatrics
Procedures in Rheumatology
Rehabilitation
Rheumatic manifestations related to systemic diseases
Rheumatoid Arthritis
Sjögren’s Syndrome
Spondyloarthritis
Systemic Lupus Erythematosus
Systemic Scleroderma
Vasculitis
Submission
The deadline for abstracts’ submission is September 27, 2020;
Abstracts must be submitted in English, in a PDF file
The title should be concise, reflect the study to be presented and be typed in the appropriated field of the submission form as well in the attached file;
There is no limit of authors per paper;
The presenter must also be on the authors list;
The abstract text should not exceed 400 words with spaces, and the limit of 250 characters for the title;
The abstract must be presented in the following sequence: background/materials and methods/results /conclusion; This suggestion does not apply to case reports/clinical trials;
The abstracts of case report must be presented in the following sequence: background/ case report/conclusion. Bibliographical references should not be included. Whereas case reports contribute in an important way to the exchange of experience among professionals, the Evaluation Committee recommends that only reports of common cases with atypical developments or of really rare cases be sent, which have important relevance;
The institution or institutions where the abstract was performed, as well as the names of the authors, MUST NOT be mentioned in the body of the text;
The contents of the abstracts should be related to the topic chosen;
Tables and figures will be accepted: Tables: tables must be numbered (e.g. Table 1) with a short descriptive title. The tables MUST be quoted/mentioned in the text. The words in the table will be counted as part of the 400 allowed for the abstract. Figures: Figures and illustrations must be numbered (e.g. Figure 1) with a short descriptive title. The figures MUST be quoted/mentioned in the text. You need permission to use pictures.
Results based on statements such as "results will be displayed" and or "data will be parsed" will not be considered. They should be exposed as clearly as possible and the conclusions should be based on the data presented;
Case reports without clear originality and/or relevance justifying their presentation will not be accepted. Studies that present only a literature review, except systematic literature reviews, will also be refused;
Trade names are not allowed, only generic names of drugs, written in lowercase letters.
References, acknowledgements and financial assistance are not mandatory and if included, must be computed as part of the abstract and should come in the end;
